{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:59:23Z","timestamp":1790067563824,"version":"4.0.1"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"Abstract<\/jats:title>\n \n Objective:<\/jats:title>\n Nonalcoholic fatty liver disease (NAFLD) is a prevalent metabolic disorder with significant health implications. This study aims to evaluate the effect of adding Saroglitazar to lifestyle modifications in improving NAFLD-related parameters compared to lifestyle modifications alone.<\/jats:p>\n <\/jats:sec>\n \n Methodology:<\/jats:title>\n A prospective observational study was conducted at the Outpatient Department of Gastroenterology, M. S. Ramaiah Hospitals, including patients diagnosed with NAFLD. Patients were divided into two groups: Group 1 received lifestyle modification counseling, and Group 2 received Saroglitazar 4 mg OD in addition to lifestyle modification counseling for 12 weeks. Liver function tests and ultrasonographic findings were assessed at baseline and after 12 weeks.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n A statistically significant improvement (\n P<\/jats:italic>\n = 0.02) in alanine transaminase (ALT) levels was observed within the treatment Group 2, along with a trend of improvement in aspartate transaminase (AST) levels (\n P<\/jats:italic>\n = 0.07). However, no significant difference in AST and ALT levels was found between the groups. Ultrasonographic improvements were noted in few patients receiving Saroglitazar, and the drug was well tolerated, with minor adverse events such as nausea and fatigue.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n The addition of Saroglitazar to lifestyle modifications showed a beneficial effect in improving NAFLD-related parameters over 12 weeks compared to lifestyle modifications alone.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/aam.aam_454_25","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T14:00:42Z","timestamp":1764338442000},"page":"1730-1733","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Addition of Saroglitazar to Lifestyle Modifications in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Observational Study"],"prefix":"10.4103","volume":"25","author":[{"given":"K.","family":"Ragottham","sequence":"first","affiliation":[{"name":"Department of Pharmacology, PES University Institute of Medical Science and Research, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mukunda","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, M. S. Ramaiah Medical College, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. V.","family":"Lokesh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, M. S. Ramaiah Medical College, Bengaluru, Karnataka, India"},{"name":"Department of Gastroenterology, Sparsh Hospital, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"R1-20260922","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jceh.2021.03.012","article-title":"Safety and efficacy of saroglitazar in nonalcoholic fatty liver patients with diabetic dyslipidemia-a prospective, interventional, pilot study","volume":"12","author":"Rajesh","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"R2-20260922","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R4-20260922","doi-asserted-by":"crossref","first-page":"21117","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: A prospective, observational, real world study","volume":"10","author":"Goyal","year":"2020","journal-title":"Sci Rep"},{"key":"R5-20260922","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"R6-20260922","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R7-20260922","first-page":"4287075","article-title":"Clinical Case series of decrease in shear wave elastography values in ten diabetic dyslipidemia patients having NAFLD with saroglitazar 4 mg: An Indian experience","author":"Roy","year":"2020","journal-title":"Case Rep Med 2020"},{"key":"R8-20260922","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/jgh3.12878","article-title":"Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience","volume":"7","author":"Chaudhuri","year":"2023","journal-title":"JGH Open"},{"key":"R9-20260922","first-page":"21","article-title":"Role of Saroglitazar in non diabetic non alcoholic fatty liver disease patients: A retrospective observational study","volume":"15","author":"Jaiswal","year":"2021","journal-title":"J Clin Diagnosis Res"},{"key":"R10-20260922","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jceh.2021.06.015","article-title":"Saroglitazar for nonalcoholic fatty liver disease: A single centre experience in 91 patients","volume":"12","author":"Padole","year":"2022","journal-title":"J Clin Exp Hepatol"}],"container-title":["Annals of African Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_454_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:00:57Z","timestamp":1790064057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_454_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/aam.aam_454_25","relation":{},"ISSN":["1596-3519","0975-5764"],"issn-type":[{"value":"1596-3519","type":"print"},{"value":"0975-5764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"2025-08-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}